Drug Trial Radar · NCT05291546
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants
Last checked: Nov 19, 2026Latest source record: Apr 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
93
Actual
Start
Apr 13, 2022
Primary completion
Apr 2, 2024
Study completion Apr 2, 2024
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Mar 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of the study is to: • Evaluate the safety and tolerability of REGN5381 and REGN9035 administered alone or sequentially. The secondary objectives of the study are to: * Evaluate the ability of single intravenous (IV) doses of REGN9035 (compared to placebo) to reverse the acute hemodynamic effects of REGN5381 * Evaluate the hemodynamic effects of single IV doses of REGN5381 * Evaluate the persistence of the hemodynamic effects of single IV doses of REGN5381 and the reversal of REGN5381 effects by REGN9035 (compared to placebo) * Evaluate the pharmacokinetics of single IV doses of REGN5381 and REGN9035 administered alone or sequentially
Conditions
- Healthy Volunteers
Interventions
REGN9035Drug
Part A: Single dose administered by IV infusion on day 1. Part B: Selected doses administered by IV infusion on day 2 or 22.
REGN5381Drug
Part B: Selected doses administered by IV infusion on day 1.
PlaceboOther
Part A: Single dose administered by IV infusion on day1. Part B: Single dose administered by IV infusion on day 1, day 2 and/or day 22.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Treatment Emergent Adverse Events (TEAEs)Time frame: Up to Day 162
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Universitair Ziekenhuis Leuven Gasthuisberg Campus
Leuven, Belgium
Charite Research Organisation GmbH
Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.